Phaseline

Targets › RV0006

RV0006: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on RV0006, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Huashan HospitalBedaquiline
ATP synthase inhibitor
RV0006Phase 3Multidrug Resistant Tuberculosis; Drug-resistant TuberculosisDec 2026

Conditions

Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1)

Modalities

–

Companies

Huashan Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.